CA3015557A1 — The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
Assigned to Indivior UK Ltd · Expires 2016-05-12 · 10y expired
What this patent protects
The disclosure provides a use of buprenorphine for treating an opioid use disorder in a human in need thereof comprising subcutaneous use of a pharmaceutical composition once per month for at least two months, wherein the pharmaceutical composition comprises: (i) about 300 mg of …
USPTO Abstract
The disclosure provides a use of buprenorphine for treating an opioid use disorder in a human in need thereof comprising subcutaneous use of a pharmaceutical composition once per month for at least two months, wherein the pharmaceutical composition comprises: (i) about 300 mg of buprenorphine free base; (ii) about 32 wt% of a poly(DL-lactide-co-glycolide) copolymer; and (iii) about 50 wt% of N-methyl-2-pyrrolidone. Also provided are uses of buprenorphine for treating an opioid use disorder or reducing opioid cravings in a human in need thereof, comprising subcutaneous use of a pharmaceutical composition once per month for at least two months, wherein the pharmaceutical composition comprises: (i) about 300 mg of buprenorphine free base; (ii) a poly(DL-lactide-co-glycolide) copolymer; and (iii) N-methyl-2-pyrrolidone.
Drugs covered by this patent
- Subutex (BUPRENORPHINE) · Purdue Pharma Lp
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.